fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Rotigotine

All products: Limited Use (codes 510)

Neupro · DIN 02403900 · 2 mg/24hr · Trans Patch

Limited Use, Reason for Use code 510 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 510 required
Write on scriptReason for Use code 510 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 510
Reason for Use code 510 For adjunctive therapy to levodopa for the treatment of patients with advanced stage Parkinson's disease (APD). Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Neupro · DIN 02403900 Manufacturer: UCB Canada Inc.; listing date 2017-09-28 Health Canada: Marketed since 2013-06-27 · brand NEUPRO · ATC N04BC09 ROTIGOTINE · form Patch · route Transdermal · ingredients ROTIGOTINE 2 MG/24HOUR · company Ucb canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Neupro: Formulary list price $3.83 per unit (the source does not state the unit; exact figure $3.8280). What the ministry pays, not the patient.

Ministry pays: $3.8280 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02403900)

Source record
DIN 02403900: Neupro Raw flags: sec12=Y, sec3=Y Item: 283620001; group id 532; item number 1438; lccId 00290; manufacturer id UCB Source form: Trans Patch; strength: 2mg/24hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.8280; ministry $3.8280 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02403900 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88867
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:36:20 Dopamine Receptor Agonists) and how they are covered
No products matched this class search: “28:36:20”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications NEUPRO (rotigotine) is indicated in adults (≥18 year of age) for: • The treatment of the signs and symptoms of idiopathic Parkinson’s disease. NEUPRO may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. • The symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) 1.1. Pediatrics The safety and efficacy of NEUPRO have not been studied in children less than 18 years of age, therefore NEUPRO is not recommended in this patient population (see 7 Warnings and Precautions, Special Populations, Pediatrics). 1.2. Geriatrics Patients above the age of 65 were included in the clinical trials for NEUPRO. NEUPRO dosing can be titrated in the normal manner but may be individualized to accommodate advanced age and potential age-related comorbidity. https://pdf.hres.ca/dpd_pm/00083389.PDF PM date: 2026-02-02 Source product: NEUPRO; DIN 02403900; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.